Dalgarno, David C.,Shakepeare, William C.,Zhu, Xiaotian,Rivera, Victor M.,Miret, Juan J.
申请号：
AU2013203904
公开号：
AU2013203904A1
申请日:
2013.04.11
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
#$%^&*AU2013203904A120130502.pdf#####Abstract The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein.
